National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment.

OBJECTIVES We estimated national and state trends in opioid agonist medication-assisted treatment (OA-MAT) need and capacity to identify gaps and inform policy decisions. METHODS We generated national and state rates of past-year opioid abuse or dependence, maximum potential buprenorphine treatment capacity, number of patients receiving methadone from opioid treatment programs (OTPs), and the percentage of OTPs operating at 80% capacity or more using Substance Abuse and Mental Health Services Administration data. RESULTS Nationally, in 2012, the rate of opioid abuse or dependence was 891.8 per 100 000 people aged 12 years or older compared with national rates of maximum potential buprenorphine treatment capacity and patients receiving methadone in OTPs of, respectively, 420.3 and 119.9. Among states and the District of Columbia, 96% had opioid abuse or dependence rates higher than their buprenorphine treatment capacity rates; 37% had a gap of at least 5 per 1000 people. Thirty-eight states (77.6%) reported at least 75% of their OTPs were operating at 80% capacity or more. CONCLUSIONS Significant gaps between treatment need and capacity exist at the state and national levels. Strategies to increase the number of OA-MAT providers are needed.

[1]  D. Salkever,et al.  Patterns in admission delays to outpatient methadone treatment in the United States. , 2011, Journal of substance abuse treatment.

[2]  C. Cunningham,et al.  Attending physicians' and residents' attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital. , 2006, Family medicine.

[3]  K. O’grady,et al.  Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. , 2013, American journal of public health.

[4]  S. Holmberg,et al.  Evolving epidemiology of hepatitis C virus in the United States. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  R. Clark,et al.  The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. , 2011, Health affairs.

[6]  D. Vlahov,et al.  Buprenorphine use: the international experience. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  M. Owens,et al.  Opioid use in Albuquerque, New Mexico: a needs assessment of recent changes and treatment availability , 2014, Addiction Science & Clinical Practice.

[8]  W. White.  Medication-Assisted Recovery from Opioid Addiction: Historical and Contemporary Perspectives , 2012, Journal of addictive diseases.

[9]  Thomas R Frieden,et al.  Medication-assisted therapies--tackling the opioid-overdose epidemic. , 2014, The New England journal of medicine.

[10]  R. Rosenblatt,et al.  Barriers to Primary Care Physicians Prescribing Buprenorphine , 2014, The Annals of Family Medicine.

[11]  Rosalie Liccardo Pacula,et al.  Supply of buprenorphine waivered physicians: the influence of state policies. , 2015, Journal of substance abuse treatment.

[12]  R. Brooner,et al.  A randomized trial of Web-based videoconferencing for substance abuse counseling. , 2014, Journal of substance abuse treatment.

[13]  C. Cunningham,et al.  Consumer attitudes about opioid addiction treatment: a focus group study in New York City. , 2013, Journal of opioid management.

[14]  Frederick J Muench,et al.  Mobile opioid agonist treatment and public funding expands treatment for disenfranchised opioid-dependent individuals. , 2014, Journal of substance abuse treatment.

[15]  S. Sigmon.  Access to treatment for opioid dependence in rural America: challenges and future directions. , 2014, JAMA psychiatry.

[16]  C. Cunningham,et al.  Factors affecting willingness to provide buprenorphine treatment. , 2009, Journal of substance abuse treatment.

[17]  C. Cunningham,et al.  A Buprenorphine Education and Training Program for Primary Care Residents: Implementation and Evaluation , 2013, Substance abuse.

[18]  J. Renner,et al.  The Physician Clinical Support System-Buprenorphine (PCSS-B): a Novel Project to Expand/Improve Buprenorphine Treatment , 2010, Journal of General Internal Medicine.

[19]  D. Buchwald,et al.  Project ECHO: a model for complex, chronic care in the Pacific Northwest region of the United States , 2012, Journal of telemedicine and telecare.

[20]  P. Levounis,et al.  Statement of the American Society of Addiction Medicine Consensus Panel on the Use of Buprenorphine in Office-Based Treatment of Opioid Addiction , 2011, Journal of addiction medicine.

[21]  Nabarun Dasgupta,et al.  Association between non-medical and prescriptive usage of opioids. , 2006, Drug and alcohol dependence.

[22]  J. Bonhomme,et al.  Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options. , 2012, Journal of the National Medical Association.

[23]  C. Cunningham,et al.  Barriers to Obtaining Waivers to Prescribe Buprenorphine for Opioid Addiction Treatment Among HIV Physicians , 2007, Journal of General Internal Medicine.

[24]  Leonard J Paulozzi,et al.  Patterns of abuse among unintentional pharmaceutical overdose fatalities. , 2008, JAMA.

[25]  D. Cheng,et al.  Office-Based Management of Opioid Dependence with Buprenorphine: Clinical Practices and Barriers , 2008, Journal of General Internal Medicine.

[26]  Leonard J. Paulozzi,et al.  Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008. , 2011, MMWR. Morbidity and mortality weekly report.

[27]  W. Kissin,et al.  Experiences of a National Sample of Qualified Addiction Specialists Who Have and Have Not Prescribed Buprenorphine for Opioid Dependence , 2006, Journal of addictive diseases.

[28]  S. Hill,et al.  The role of Cochrane reviews in informing international guidelines: a case study of using the Grading of Recommendations, Assessment, Development and Evaluation system to develop World Health Organization guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. , 2015, Addiction.

[29]  C. Schuster,et al.  Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians. , 2010, Journal of substance abuse treatment.

[30]  B. Tempalski,et al.  Distance Traveled and Cross-State Commuting to Opioid Treatment Programs in the United States , 2011, Journal of environmental and public health.

[31]  J. Zibbell,et al.  Risk factors for HCV infection among young adults in rural New York who inject prescription opioid analgesics. , 2014, American journal of public health.

[32]  G. Bart.  Maintenance Medication for Opiate Addiction: The Foundation of Recovery , 2012, Journal of addictive diseases.

[33]  H. Knudsen,et al.  Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation. , 2011, Addictive behaviors.

[34]  Li-Hui Chen,et al.  Trends in drug-poisoning deaths involving opioid analgesics and heroin : United States, 1999–2012 , 2014 .

[35]  Adoption and diffusion of evidence-based addiction medications in substance abuse treatment. , 2014, Health services research.

[36]  P. Roman,et al.  Adoption of injectable naltrexone in U.S. substance use disorder treatment programs. , 2015, Journal of studies on alcohol and drugs.

[37]  Kenneth E. Carlson,et al.  The ecology of prescription opioid abuse in the USA: geographic variation in patients' use of multiple prescribers (“doctor shopping”) , 2014, Pharmacoepidemiology and drug safety.

[38]  J. Hahn,et al.  Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. , 2014, JAMA internal medicine.

[39]  Christopher M. Jones,et al.  Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers - United States, 2002-2004 and 2008-2010. , 2013, Drug and alcohol dependence.

[40]  R. Merrill,et al.  Unintentional Prescription Opioid-Related Overdose Deaths: Description of Decedents by Next of Kin or Best Contact, Utah, 2008–2009 , 2013, Journal of General Internal Medicine.

[41]  T. Kresina,et al.  Improving Public Health Through Access to and Utilization of Medication Assisted Treatment , 2011, International journal of environmental research and public health.

[42]  C. Green,et al.  Training rural practitioners to use buprenorphine; using The Change Book to facilitate technology transfer. , 2004, Journal of substance abuse treatment.

[43]  Dingcai Cao,et al.  Client and Program Characteristics Associated with Wait Time to Substance Abuse Treatment Entry , 2013, The American journal of drug and alcohol abuse.

[44]  H. Surratt,et al.  The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. , 2014, JAMA psychiatry.

[45]  Lori J. Ducharme,et al.  State policy influence on the early diffusion of buprenorphine in community treatment programs , 2008, Substance abuse treatment, prevention, and policy.

[46]  Marcia Valenstein,et al.  Association between Opioid Prescribing Patterns and Opioid Overdose-related Deaths Downloaded From: Http://jama.jamanetwork.com/ by a Penn State Milton S Hershey Med Ctr User on 08/01/2013 , 2022 .

[47]  A. Daniels,et al.  A Novel Community-Based Buprenorphine Program: Client Description and Initial Outcomes , 2014, Journal of addiction medicine.